DXCM · DexCom

The thesis

Dexcom's third-quarter beat, 25.3% operating margin and raised fiscal 2026 outlook give the shares a modest edge over the S&P 500, after a sector-wide sell-off in diabetes-device stocks erased the post-report gain. The next test is a Medicare coverage decision for type 2 diabetes patients who do not use insulin, which management expects by the end of 2026. International growth of 5% is the weak spot.

The shares closed at $80.34 on 11 November 2026. That is below the $88.48 close of 4 November 2026 and above the $79.41 close of 6 November 2026. Over the three sessions since 6 November 2026 the shares have traded between $79.41 and $81.07, so the decline has stopped without a recovery. Dexcom has issued no results, guidance or filing since the 29 October 2026 report that changes the operating picture.

The price reflects sector doubts more than anything Dexcom has said. On 6 November 2026 Dexcom fell 6.0%, Insulet 6.2% and Tandem Diabetes Care 6.0% while the S&P 500 rose 0.3%, Trefis reported. Every analyst target set after the report sits above the 11 November 2026 close.

Bullish and bearish views on DexCom, Inc.

The bull case on DexCom, Inc. (DXCM), in brief: fiscal 2026 guidance moved up. The bear case: international growth slowed to 5%.

Bull case

• Fiscal 2026 guidance moved up. On 29 October 2026 Dexcom raised its revenue range to $5.20–$5.25 billion, from $5.18–$5.25 billion. Non-GAAP operating-margin guidance rose to about 24%, from 23.5–24%.
• U.S. revenue grew 14%. Third-quarter U.S. revenue was $969.8 million, according to the company's 29 October 2026 release. Total revenue was $1.344 billion, up 11%, against a $1.327 billion estimate, Benzinga reported.
• Margins keep widening. The non-GAAP operating margin, which excludes items such as stock compensation, was 25.3% in the third quarter against 22.6% a year earlier. Gross margin was 65.1% against 61.3%, the company reported on 29 October 2026.
• Medicare could double covered lives. Leerink analyst Mike Kratky wrote that the expansion would take Dexcom's covered lives from about 15 million to 30 million, Medtech Dive reported on 15 October 2026. In the CONNECT trial, published in the New England Journal of Medicine, A1C (a three-month blood-sugar average) fell from 8.8% to 7.2% with the G7 sensor over 26 weeks, against 8.7% to 8% with routine care.
• The product list keeps widening. Health Canada approved the G7 sensor for use with the myLoop automated insulin delivery system, powered by CamAPS FX, Dexcom announced on 9 November 2026. Dexcom said on 28 October 2026 that the G7 15 Day sensor would launch in Canada in November.
• Capital returns are rising. Dexcom completed its $1 billion repurchase goal for 2026. The board authorized up to a further $1 billion on 29 October 2026.
• Every post-report target sits above the price. Barclays moved to $120, UBS to $107 from $102, Canaccord Genuity to $97, StoneX to $93 and JP Morgan to $85 on 30 October 2026 and 31 October 2026. MarketBeat listed the consensus target at $95.50 on 4 November 2026.

Bear case

• International growth slowed to 5%. Third-quarter international revenue was $374.7 million, up 5% as reported. Abbott said on 21 October 2026 that it expects diabetes-care growth in the low-to-mid single digits for the next few quarters, citing international pricing pressure.
• The Medicare date is unconfirmed. Medtech Dive reported on 15 October 2026 that timing for the expansion was still unknown. A 12 November 2026 search of trade sources found no published CMS (Centers for Medicare & Medicaid Services) proposal for non-insulin patients. The year-end timetable is Dexcom's own expectation.
• The whole diabetes-device group is under pressure. Trefis linked the 6 November 2026 decline across Dexcom, Insulet and Tandem to Tandem's warning that a slower shift to pharmacy distribution could weigh on its 2027 growth. Dexcom fell as hard as its peers on no news of its own.
• 2027 carries named headwinds. Management guided to 2027 growth above 10% on the 29 October 2026 call. It cited the start-up of its Ireland plant and a CVS contract change as drags.
• The valuation leaves little room. Trefis put Dexcom at 5.8 times trailing revenue on 6 November 2026, against 3.1 times for the S&P 500.
• A U.S. competitor launches in December. Abbott has scheduled the U.S. launch of its Libre Duo glucose-ketone sensor for December 2026, Drug Delivery Business reported.

Price setup

The shares closed at $80.34 on 11 November 2026, down 12.2% from the $91.48 close of 13 August 2026. The last close is 13.2% below the 52-week intraday high of $92.59 set on 24 August 2026. The 52-week closing low was $57.56 on 29 April 2026.

The shares sit below the 50-day moving average of $84.59 and above the 200-day moving average of $74.99, both as of 11 November 2026. The $79.41 close of 6 November 2026 is the floor of the trading range since the sell-off. A recovery above the 50-day average would show the market moving back toward the post-report reading; the 200-day average is the next reference below.

SEC Form 4 filings show no insider buying. Four executives, including Chief Executive Jacob Leach and Chief Financial Officer Jereme Sylvain, each had 1,451 shares withheld for tax at $79.41 on 8 November 2026, a routine vesting event. The most recent open-market sales ran through Rule 10b5-1 plans: 2,565 shares at $78.62 on 27 October 2026 and 1,700 shares at $85.48 on 15 October 2026. Management presents at the Jefferies Global Healthcare Conference in London on 17 November 2026, the first scheduled public update since the sell-off.

Catalysts ahead

• 17 November 2026: Dexcom management company update at the Jefferies Global Healthcare Conference in London. The first scheduled public update since the 5 November 2026 and 6 November 2026 sector sell-off; shows whether management restates the above-10% 2027 growth framing and the year-end Medicare timetable.
• ~30 November 2026 (est.): G7 15 Day sensor becomes available to adults in Canada during November 2026. First market outside the U.S. for the longer-wear sensor while international growth runs at 5%; early uptake shows whether new products can lift overseas sales.
• ~15 December 2026 (est.): Abbott's U.S. launch of the Libre Duo glucose-ketone sensor, reported for December. The next direct competitive test in the U.S., where Dexcom revenue grew 14% in the third quarter.
• ~31 December 2026 (est.): End of management's timetable for a CMS coverage decision on CGMs for non-insulin type 2 diabetes. A decision would turn the CONNECT trial evidence into reimbursement from mid-2027; no decision would delay the type 2 growth case again.
• ~25 February 2027 (est.): Dexcom fourth-quarter 2026 report and first formal 2027 guidance. Shows the size of the Ireland plant margin drag and the CVS contract change, and whether international growth holds at 5% or better.

What would change the view

A daily close below $76, under the 6 November 2026 close of $79.41 and the post-report trading range, which would show the sector sell-off turning into a rejection of the raised outlook; secondarily, no CMS proposal by 31 December 2026 or 2027 guidance below 10% growth.

The risks this note tracks, each with what would confirm it:

• International CGM price competition, which Abbott described on 21 October 2026, reaches Dexcom. Confirmed by: international revenue growth below the third quarter's 5%, or Dexcom disclosing lower overseas selling prices at the next report.
• CMS coverage for non-insulin type 2 diabetes slips again or comes out narrower than expected. Confirmed by: no CMS proposal published by 31 December 2026, or a proposal that leaves out non-insulin patients.
• Sector-wide doubts about 2027 diabetes-device growth, raised by Tandem's pharmacy-shift warning, keep pressure on Dexcom shares. Confirmed by: further same-day declines across Dexcom, Insulet and Tandem with no Dexcom-specific news, or peers cutting 2027 growth expectations.
• Ireland plant start-up costs drag on margins longer than the few quarters management described. Confirmed by: 2027 guidance with a non-GAAP operating margin below fiscal 2026's roughly 24%.
• The CVS contract change cuts 2027 U.S. growth more than management's above-10% framing allows. Confirmed by: formal 2027 revenue guidance implying growth of 10% or less at the fourth-quarter report.
• Abbott's Libre Duo launch takes U.S. share from Dexcom. Confirmed by: Abbott reporting faster U.S. Libre growth in early 2027 while Dexcom's U.S. growth slows from 14%.
• The Cybersecurity incident and class actions prove larger than Dexcom has described. Confirmed by: an 8-K under Item 1.05, patient breach notices, or quantified incident or litigation costs.

What it trades with

The 6 November 2026 session shows how closely Dexcom trades with other diabetes-device makers. Dexcom fell 6.0%, Insulet 6.2% and Tandem 6.0%, while the Nasdaq Composite rose 1.1% and the health-care sector XLV slipped 0.1%, Trefis reported. Abbott and Medtronic, whose diabetes units sit inside larger companies, fell less. News from Tandem, Insulet or Abbott's diabetes unit can move Dexcom shares on days when Dexcom itself reports nothing. A CMS coverage decision would apply to Abbott's Libre as well as to Dexcom's G7.